Christopher Bunka - 17 Mar 2026 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Reporting relationship
Director
Issuer ticker
LEXX
Reported as of
17 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Mar 2026, 11:37:13 UTC
Prior SEC filing
30 Jul 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/Chris Bunka/

Key filing fact

Christopher Bunka filed Form 4 for Lexaria Bioscience Corp. (LEXX) on 18 Mar 2026.

Key facts

  • This page summarizes Christopher Bunka's Form 4 filing for Lexaria Bioscience Corp. (LEXX).
  • 1 reported transaction and 7 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 11:37.

Change

  • Previous filing in this sequence was filed on 30 Jul 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001103780 Primary reporting owner

BUNKA CHRISTOPHER

Relationship
Director
Address
SUITE 100, 740 MCCURDY ROAD, KELOWNA, BRITISH COLUMBIA, CANADA
Signature
/Chris Bunka/
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEXX transaction

common shares

Gift

Transaction value
Shares
-100,000
Change %
-27%
Price
$0.000000*
Shares after
273,543
Date
17 Mar 2026
Ownership
Direct
Footnotes
F1
LEXX holding

common shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
373,543
Date
17 Mar 2026
Ownership
Direct
LEXX holding

common shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
281,912
Date
17 Mar 2026
Ownership
Private Holding Company

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
26,000
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
26,000
Exercise price
$3.00
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
49,334
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
23,334
Exercise price
$3.00
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
64,334
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
15,000
Exercise price
$3.00
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
94,334
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$2.91
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
124,334
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
30,000
Exercise price
$1.15
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
173,834
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
49,500
Exercise price
$2.36
LEXX holding Derivative

Stock Options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
184,834
Date
17 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
11,000
Exercise price
$1.04
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The 100,000 shares were gifted back to Lexaria Bioscience Corp. and returned to treasury.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .